<DOC>
	<DOCNO>NCT01764555</DOCNO>
	<brief_summary>This study investigate pharmacokinetics acetaminophen morbidly obese patient versus normal weight patient . Specifically different metabolic pathway acetaminophen morbidly obese adult investigate ; glucuronidation , sulphation CYP2E1 ( cytochrome P450 2E1 ) oxidation</brief_summary>
	<brief_title>Pharmacokinetics Acetaminophen Morbidly Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Inclusion criterion morbidly obese patient : BMI &gt; 40 kg/m2 undergo bariatric surgery . Patients 18 60 year old ASA physical classification II III All racial ethnic group include Inclusion criterion control group : BMI 18 25 kg/m2 undergo general surgery Patients 18 60 year old ASA ( American Society Anesthesiology ) physical classification I , II III All racial ethnic group include Exclusion criterion study arm : Renal insufficiency Liver disease Patients GilbertMeulengracht syndrome Chronic alcohol intake use alcohol within last 72 hour Pregnancy breastfeed Patients treat drug know affect CYP2E1 UGT ( UDP glucuronosyltransferase ) Diabetes mellitus type II patient Smoking Acetaminophen intake study ( 24 hour study )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>